Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 9/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950331 | 1.00 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL790657 | 1.00 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Imidazole SCHEMBL9187249 | 0.88 | SRD5A2 (0.45) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL6673554 | 0.85 | SRD5A1 (0.42) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8059923 | 0.81 | SRD5A1 (0.48) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8135268 | 0.81 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8135264 | 0.81 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL4263946 | 0.80 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL4263941 | 0.80 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL7901226 | 0.79 | SRD5A1 (0.55) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872135-B2 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2011-01-18 | — | — | US | claimed |
| EP-1523490-B1 | METHOD FOR INTRODUCING A 1,2 DOUBLE BOND INTO 3-OXO-4-AZASTEROID COMPOUNDS | SIEGFRIED GENERICS INT AG (CH) | 2009-12-23 | — | — | EP | claimed |
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2006-05-11 | — | — | US | claimed |
| EP-1335930-B1 | Process for the preparation of 3-oxo-4-azasteroids | GLAXO GROUP LTD (GB) | 2004-10-13 | — | — | EP | claimed |
| US-6794508-B2 | Process | SMITHKLINE BEECHAM CORPORATION | 2004-09-21 | — | — | US | claimed |
| US-20040049042-A1 | Process | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | claimed |
| EP-1335930-A2 | PROCESS | GLAXO GROUP LIMITED (GB) | 2003-08-20 | — | — | EP | claimed |
| WO-2002046207-A2 | PROCESS | GLAXO GROUP LIMITED (GB) | 2002-06-13 | — | — | WO | claimed |
| WO-2013001322-A1 | PROCESS FOR THE SYNTHESIS OF (5α,17β)-N-[(2,5-BIS(TRIFLUOROMETHYL)-PHENYL]-3-OXO-4-AZA-5-ANDROST-1-ENE-17-CARBOXAMIDE | RICHTER GEDEON NYRT. (HU) | 2013-01-03 | — | — | WO | disclosed |
| US-7872135-B2 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2011-01-18 | — | — | US | disclosed |
| US-7872135-B2 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2011-01-18 | — | — | US | disclosed |
| CN-1319985-C | Method for introducing a 1,2 double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED GENERICS INT AG (CH) | 2007-06-06 | — | — | CN | disclosed |
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2006-05-11 | — | — | US | disclosed |
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2006-05-11 | — | — | US | disclosed |
| WO-2004007523-A1 | METHOD FOR INTRODUCING A 1,2 DOUBLE BOND INTO 3-OXO-4-AZASTEROID COMPOUNDS | SIEGFRIED GENERICS INTERNATIONAL AG (CH) | 2004-01-22 | — | — | WO | disclosed |
| EP-1335930-A2 | PROCESS | GLAXO GROUP LIMITED (GB) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002046207-A2 | PROCESS | GLAXO GROUP LIMITED (GB) | 2002-06-13 | — | — | WO | disclosed |
| US-5494914-A | USEFUL FOR TREATMENT OF DISEASES WHOSE PROGRESS IS AIDED BY ACTIVATION OF ANDROGEN RECEPTORS | ENDORECHERCHE (CA) | 1996-02-27 | — | — | US | disclosed |
| EP-0641211-A1 | INHIBITORS OF TESTOSTERONE 5$g(a)-REDUCTASE ACTIVITY | ENDORECHERCHE INC. (CA) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023053-A1 | INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY | ENDORECHERCHE INC. (CA) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | NR3C2, NR5A1, CYP11B1 | SRD5A1 14/4885SRD5A2 7/4885LMNA 1712/4885 |
| US-20040049042-A1 | Process | SRD5A2, SRD5A1, HSD3B1 | SRD5A1 2/4885SRD5A2 1/4885LMNA 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.